Hints and tips:
...The deal is the largest pharmaceutical transaction since AbbVie agreed to buy Allergan for $63bn in 2019 and signals a rebound in mergers and acquisitions following a dip in activity last year, according...
...Allergan could not be reached for comment. Cinven declined to comment....
...The acquisition is the biggest transaction in pharmaceuticals since 2019, when AbbVie acquired Allergan for $63bn, and the largest deal to target a US company in any sector this year....
...It has limited the amount of stock it is issuing to Allergan shareholders so that its own investors will not have a vote. But with shares off so sharply, investors are making their views clear anyway....
...taxes by capturing Allergan’s Irish tax incorporation....
...Appaloosa currently holds a 0.35 per cent stake in Allergan, according to Eikon data, making it Allergan’s 44th largest shareholder....
...The Financial Times earlier this month disclosed that JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Allergan on a planned $63bn...
...Sign up here to Market Forces, Mike Mackenzie’s daily analysis of what’s moving global markets Beyond the Square Mile US drugmaker AbbVie has agreed to buy Allergan, the Irish-domiciled maker of Botox...
...Shire’s appeal to Allergan is not hard to fathom. Allergan shed its original generics business for $33bn in 2016, in a well-timed deal. Instead, it wants to acquire early-stage drugs....
...Allergan said it had not yet made an offer to Shire....
...Shire on Friday confirmed that Allergan had backed away....
...Allergan briefly entered the fray just hours later, disclosing it was considering a bid but had not yet made an official offer....
...According to Silvana van Schaik, manager for healthcare and chemicals at research provider Sustainalytics, the 2016 outcry persuaded some pharma companies, led by Ireland-headquartered Allergan, to commit...
...The firm’s original investment in Allergan was a money-spinner, reaping gains of $2.3bn before the company agreed a sale to Actavis....
...A year ago, Brent Saunders, chief executive of drug titan Allergan PLC, enjoyed a reputation as the last pharma boss with a honourable reputation....
...Tribe seeks more controversial patent deals The tribe at the centre of the Allergan deal — the Saint Regis Mohawks — has not limited its patent strategy to the pharmaceuticals sector, recently signing a...
...Allergan of the US considered a counter bid, before ruling itself out for now. Yet mention of Allergan only highlights the contrast between US and UK political interventions....
...Balance sheets remain in very good shape and there is limited pressure on costs (especially land)....
...Other large drugmakers, including Allergan, GlaxoSmithKline, Gilead, Shire, Biogen, Teva, Baxter and Viiv also increased the US list prices of their medicines on January 1, according to the data....
...He has since tried to reshape the drugmaker through attempted acquisitions of Anglo-Swedish AstraZeneca and Dublin-based Allergan, although both tie-ups were thwarted by politicians worried about jobs and...
...In August, Teva reported a $6bn loss and slashed its dividend after incurring a $6.1bn impairment charge on its US generics business, which includes the Allergan unit it bought last year for about $40.5bn...
...The low unemployment rate of 4.3 per cent also suggests there is limited spare capacity in the economy....
...The relevant SEC filings were made by Allergan, Inc. prior to its acquisition by Actavis plc....
...The company is weathering a rough patch, and recently come under criticism from shareholders for its $40bn acquisition of Allergan’s generic drugs business last year, for which some shareholders and analysts...
International Edition